The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Epigenetic Characterization of the FMR1 Gene and Aberrant Neurodevelopment in Human Induced Pluripotent Stem Cell Models of Fragile X Syndrome
Open accessAbstract
Fragile X syndrome (FXS) is the most common inherited cause of intellectual disability. In addition to cognitive deficits, FXS patients exhibit hyperactivity, attention deficits, social difficulties, anxiety, and other autistic-like behaviors. FXS is caused by an expanded CGG trinucleotide repeat in the 5' untranslated region of the Fragile X Mental Retardation (FMR1) gene leading to epigenetic silencing and loss of expression of the Fragile X Mental Retardation protein (FMRP). Despite the known relationship between FMR1 CGG repeat expansion and FMR1 silencing, the epigenetic modifications observed at the FMR1 locus, and the consequences of the loss of FMRP on human neurodevelopment and neuronal function remain poorly understood. To address these limitations, we report on the generation of induced pluripotent stem cell (iPSC) lines from multiple patients with FXS and the characterization of their differentiation into post-mitotic neurons and glia. We show that clones from reprogrammed FXS patient fibroblast lines exhibit variation with respect to the predominant CGG-repeat length in the FMR1 gene. In two cases, iPSC clones contained predominant CGG-repeat lengths shorter than measured in corresponding input population of fibroblasts. In another instance, reprogramming a mosaic patient having both normal and pre-mutation length CGG repeats resulted in genetically matched iPSC clonal lines differing in FMR1 promoter CpG methylation and FMRP expression. Using this panel of patient-specific, FXS iPSC models, we demonstrate aberrant neuronal differentiation from FXS iPSCs that is directly correlated with epigenetic modification of the FMR1 gene and a loss of FMRP expression. Overall, these findings provide evidence for a key role for FMRP early in human neurodevelopment prior to synaptogenesis and have implications for modeling of FXS using iPSC technology. By revealing disease-associated cellular phenotypes in human neurons, these iPSC models will aid in the discovery of novel therapeutics for FXS and other autism-spectrum disorders sharing common pathophysiology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Friedreich's Ataxia: Autosomal Recessive Disease Caused by an Intronic GAA Triplet Repeat Expansion
Campuzano, V., Montermini, L., Moltò, M. D., Pianese, L., Cossée, M., Cavalcanti, F., Monros, E., Rodius, F., Duclos, F., Monticelli, A., et al. (1996) · Science · doi:10.1126/science.271.5254.1423 · Cited by 2,786 · cited 2×
“In this manner, FXS can be considered to be an epigenetic disorder and there is growing evidence that the epigenetic state of the FMR1 gene, rather than the CGG-repeat length itself, is the key determinant of FXS pathogenesis and also treatment response [11,12,13,14].”
BackgroundWalker, F. O. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60111-1 · Cited by 2,603
Reprogramming of human somatic cells to pluripotency with defined factors
Park, I.-H., Zhao, R., West, J. A., Yabuuchi, A., Huo, H., Ince, T. A., Lerou, P. H., Lensch, M. W., & Daley, G. Q. (2008) · Nature · doi:10.1038/nature06534 · Cited by 2,436
Itskovitz-Eldor, J., Schuldiner, M., Karsenti, D., Eden, A., Yanuka, O., Amit, M., Soreq, H., & Benvenisty, N. (2000) · Molecular Medicine · doi:10.1007/bf03401776 · Cited by 1,500
Instability of a 550-Base Pair DNA Segment and Abnormal Methylation in Fragile X Syndrome
Oberlé, I., Rousseau, F., Heitz, D., Kretz, C., Devys, D., Hanauer, A., Boué, J., Bertheas, M. F., & Mandel, J. L. (1991) · Science · doi:10.1126/science.252.5009.1097 · Cited by 1,499
Tassone, F., Hagerman, R. J., Taylor, A. K., Gane, L. W., Godfrey, T. E., & Hagerman, P. J. (2000) · The American Journal of Human Genetics · doi:10.1086/302720 · Cited by 774
FMR1 Protein: Conserved RNP Family Domains and Selective RNA Binding
Ashley, C. T., Wilkinson, K. D., Reines, D., & Warren, S. T. (1993) · Science · doi:10.1126/science.7692601 · Cited by 741
FMR1 and the fragile X syndrome: Human genome epidemiology review
Crawford, D. C., Acuña, J. M., & Sherman, S. L. (2001) · Genetics in Medicine · doi:10.1097/00125817-200109000-00006 · Cited by 711 · cited 3×
“Clinical manifestations of the syndrome include cognitive abnormalities ranging from mild learning impairment to severe mental retardation which often progressively increases with age [3,4,5,6].”
BackgroundA transient three-plasmid expression system for the production of high titer retroviral vectors
Soneoka, Y., Cannon, P. M., Ramsdale, E. E., Griffiths, J. C., Romano, G., Kingsman, S. M., & Kingsman, A. J. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.4.628 · Cited by 690
DNA methylation represses FMR-1 transcription in fragile X syndrome
Sutcliffe, J. S., Nelson, D. L., Zhang, F., Pieretti, M., Caskey, C. T., Saxe, D., & Warren, S. T. (1992) · Human Molecular Genetics · doi:10.1093/hmg/1.6.397 · Cited by 680
The protein product of the fragile X gene, FMR1, has characteristics of an RNA-binding protein.
Siomi, H., Siomi, M. C., Nussbaum, R. L., & Dreyfuss, G. (1993) · Cell · doi:10.1016/0092-8674(93)90420-u · Cited by 641
Jacquemont, S., Curie, A., des Portes, V., Torrioli, M. G., Berry-Kravis, E., Hagerman, R. J., Ramos, F. J., Cornish, K., He, Y., Paulding, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001708 · Cited by 609 · cited 1×
“In this manner, FXS can be considered to be an epigenetic disorder and there is growing evidence that the epigenetic state of the FMR1 gene, rather than the CGG-repeat length itself, is the key determinant of FXS pathogenesis and also treatment response [11,12,13,14].”
BackgroundAdvances in the Treatment of Fragile X Syndrome
Hagerman, R. J., Berry-Kravis, E., Kaufmann, W. E., Ono, M. Y., Tartaglia, N., Lachiewicz, A., Kronk, R., Delahunty, C., Hessl, D., Visootsak, J., et al. (2009) · Pediatrics · doi:10.1542/peds.2008-0317 · Cited by 596
Geschwind, D. H. (2009) · Annual Review of Medicine · doi:10.1146/annurev.med.60.053107.121225 · Cited by 512
Guidelines and Techniques for the Generation of Induced Pluripotent Stem Cells
Maherali, N., & Hochedlinger, K. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2008.11.008 · Cited by 486
A PEDIGREE OF MENTAL DEFECT SHOWING SEX-LINKAGE
Martin, J. P., & Bell, J. (1943) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.6.3-4.154 · Cited by 481
The Pathophysiology of Fragile X Syndrome
Penagarikano, O., Mulle, J. G., & Warren, S. T. (2007) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.8.080706.092249 · Cited by 420 · cited 3×
“Loss of the fragile X mental retardation protein (FMRP) has been shown to be causative for the cognitive and behavioral impairments of FXS [6].”
BackgroundAntar, L. N., Afroz, R., Dictenberg, J. B., Carroll, R. C., & Bassell, G. J. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0099-04.2004 · Cited by 411
Urbach, A., Bar-Nur, O., Daley, G. Q., & Benvenisty, N. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.04.005 · Cited by 407
Translational Suppression by Trinucleotide Repeat Expansion at FMR1
Feng, Y., Zhang, F., Lokey, L. K., Chastain, J. L., Lakkis, L., Eberhart, D., & Warren, S. T. (1995) · Science · doi:10.1126/science.7732383 · Cited by 358
Eiges, R., Urbach, A., Malcov, M., Frumkin, T., Schwartz, T., Amit, A., Yaron, Y., Eden, A., Yanuka, O., Benvenisty, N., et al. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.09.001 · Cited by 286
Tost, J., Dunker, J., & Gut, I. G. (2003) · BioTechniques · doi:10.2144/03351md02 · Cited by 250
Luo, Y., Shan, G., Guo, W., Smrt, R. D., Johnson, E. B., Li, X., Pfeiffer, R. L., Szulwach, K. E., Duan, R., Barkho, B. Z., et al. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1000898 · Cited by 237
Maddalena, A., Richards, C. S., McGinniss, M. J., Brothman, A., Desnick, R. J., Grier, R. E., Hirsch, B., Jacky, P., McDowell, G. A., Popovich, B., et al. (2001) · Genetics in Medicine · doi:10.1097/00125817-200105000-00010 · Cited by 231
Ku, S., Soragni, E., Campau, E., Thomas, E. A., Altun, G., Laurent, L. C., Loring, J. F., Napierala, M., & Gottesfeld, J. M. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.09.014 · Cited by 212
Self-citationAltered differentiation of neural stem cells in fragile X syndrome
Castrén, M., Tervonen, T., Kärkkäinen, V., Heinonen, S., Castrén, E., Larsson, K., Bakker, C. E., Oostra, B. A., & Åkerman, K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508995102 · Cited by 176
Mosaicism in fragile X affected males
Nolin, S. L., Glicksman, A., Houck, G. E., Brown, W. T., & Dobkin, C. S. (1994) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320510444 · Cited by 164
FMRP Involvement in Formation of Synapses among Cultured Hippocampal Neurons
Braun, K. A., & Segal, M. (2000) · Cerebral Cortex · doi:10.1093/cercor/10.10.1045 · Cited by 157
Stem Cells and Drug Discovery: The Beginning of a New Era?
Rubin, L. L. (2008) · Cell · doi:10.1016/j.cell.2008.02.010 · Cited by 150
Instability of a (CGG)98 repeat in the Fmr1 promoter
Bontekoe, C. J. M. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.16.1693 · Cited by 143
Wöhrle, D., Salat, U., Hameister, H., Vogel, W., & Steinbach, P. J. (2001) · The American Journal of Human Genetics · doi:10.1086/322739 · Cited by 126
Protocols for cytogenetic studies of human embryonic stem cells
Meisner, L. F., & Johnson, J. L. (2008) · Methods · doi:10.1016/j.ymeth.2008.03.005 · Cited by 119
Kumari, D., & Usdin, K. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq394 · Cited by 103
Godde, J. S., Kass, S. U., Hirst, M. C., & Wolffe, A. P. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.40.24325 · Cited by 88
Brakensiek, K., Wingen, L. U., Länger, F. P., Kreipe, H. H., & Lehmann, U. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2007.072629 · Cited by 78
Chromatin Remodeling in the Noncoding Repeat Expansion Diseases
Kumari, D., & Usdin, K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.r800026200 · Cited by 71
Normal Neurogenesis but Abnormal Gene Expression in Human Fragile X Cortical Progenitor Cells
Bhattacharyya, A., McMillan, E., Wallace, K., Tubon, T. C., Capowski, E. E., & Svendsen, C. N. (2008) · Stem Cells and Development · doi:10.1089/scd.2007.0073 · Cited by 63
FMR1 Premutation Allele (CGG)(81) Is Stable in Mice
Bontekoe, C. J. M., de Graaff, E., Nieuwenhuizen, I. M., Willemsen, R., & Oostra, B. A. (1997) · European Journal of Human Genetics · doi:10.1159/000484780 · Cited by 57
FMR1 premutation allele (CGG)81 is stable in mice.
Bontekoe, C. J. M., de Graaff, E., Im, N., Willemsen, R., & Oostra, B. A. (1997) · PubMed · Cited by 55
The Friedreich ataxia critical region spans a 150-kb interval on chromosome 9q13.
Montermini, L., Rodius, F., Pianese, L., Moltò, Cossée, M., Campuzano, V., Cavalcanti, F., Monticelli, A., Palau, F., & Gyapay, G. (1995) · Europe PMC (PubMed Central) · Cited by 42
Microporous Membrane Growth Substrates for Embryonic Stem Cell Culture and Differentiation
Sheridan, S. D., Gil, S., Wilgo, M., & Pitt, A. M. (2008) · Methods in cell biology · doi:10.1016/s0091-679x(08)00003-4 · Cited by 32
Self-citationPropagation of human embryonic and induced pluripotent stem cells in an indirect co-culture system
Abraham, S., Sheridan, S. D., Laurent, L. C., Albert, K. M., Stubban, C., Ulitsky, I., Miller, B. B., Loring, J. F., & Rao, R. R. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.01.101 · Cited by 18
Self-citationDifferentiation of Neuronal Cells in Fragile X Syndrome
Castrén, M. L. (2006) · Cell Cycle · doi:10.4161/cc.5.14.3096 · Cited by 14
Datta, S., Alam, M. P., Majumdar, S. S., Mehta, A. K., Maiti, S., Wadhwa, N., & Brahmachari, V. (2011) · Chromosome Research · doi:10.1007/s10577-011-9206-7 · Cited by 11
Cited by
Individual brain organoids reproducibly form cell diversity of the human cerebral cortex
Velasco, S., Kedaigle, A. J., Simmons, S. K., Nash, A., Rocha, M., Quadrato, G., Paulsen, B., Nguyen, L., Adiconis, X., Regev, A., et al. (2019) · Nature · doi:10.1038/s41586-019-1289-x · Cited by 1,094
Sellgren, C. M., Gracias, J., Watmuff, B., Biag, J. D., Thanos, J. M., Whittredge, P. B., Fu, T., Worringer, K., Brown, H. E., Wang, J., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-018-0334-7 · Cited by 786
Self-citationEngineered In Vitro Disease Models
Benam, K. H., Dauth, S., Hassell, B., Herland, A., Jain, A., Jang, K.-J., Karalis, K., Kim, H. J., MacQueen, L., Mahmoodian, R., et al. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040418 · Cited by 554
Zoghbi, H. Y., & Beaudet, A. L. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a019497 · Cited by 362
Sugathan, A., Biagioli, M., Golzio, C., Erdin, S., Blumenthal, I., Manavalan, P., Ragavendran, A., Brand, H., Lucente, D., Miles, J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1405266111 · Cited by 342
Self-citation
Metadata
- Authors
- Sheridan, S. D., Theriault, K. M., Reis, S. A., Zhou, F., Madison, J. M., Daheron, L., Loring, J. F., & Haggarty, S. J.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-10-12
- Volume
- 6
- Issue
- 10
- Pages
- e26203
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2048834720
- Cited by
- 317
- References
- 45
- FWCI
- 14.43
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.